CAR-T cell therapy
May 13, 2024
Bispecific and Trispecific Antibodies: Are They Better Than CAR-Ts?
CAR-T therapy has been given the green light for treating blood cancers, but it hasn’t demonstrated sustained effectiveness against solid tumors thus far. The focus of ongoing CAR-T development leans heavily toward blood cancers rather than solid ones. On the other hand, bispecific antibodies have gained approval f...
Read More...
May 07, 2024
Boehringer Ingelheim’s Diabetic Macular Ischemia Study; Novartis’ Mariana Oncology Acquisition; Astellas and Poseida Therapeutics Partnership; Prime Medicine’s PM359 IND; Pfizer’s TIVDAK FDA Approval
Boehringer Ingelheim Announces Promising Findings From Groundbreaking Study on Diabetic Macular Ischemia Boehringer Ingelheim released encouraging results from the HORNBILL Phase I/IIa trial of BI 764524, marking the pioneering investigation into a potential therapy for individuals with diabetic macular is...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
